FDA Further Complicates Endo's Outlook
Removing Opana from the market adds another headwind to this high-risk firm's competitive pressure in its branded and generics segments, high financial leverage concerns, and ongoing mesh litigation.
FDA has requested
Morningstar Premium Members gain exclusive access to our full analyst reports, including fair value estimates, bull and bear breakdowns, and risk analyses. Not a Premium Member? Get this and other reports immediately when you try Morningstar Premium free for 14 days.